Skip to main content
Cell Death & Disease logoLink to Cell Death & Disease
. 2020 Nov 23;11(11):1006. doi: 10.1038/s41419-020-03208-z

Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer

Haoran Feng 1,2,#, Kun Liu 1,3,#, Xiaonan Shen 4,#, Juyong Liang 1,2, Changgang Wang 1,3, Weihua Qiu 1,2,3,, Xi Cheng 1,2,3,, Ren Zhao 1,2,3,
PMCID: PMC7683607  PMID: 33230188

Correction to: Cell Death and Disease

10.1038/s41419-020-03111-7 published online 24 October 2020

The original version of this Article was updated shortly after publication following a mistake at proof stage, which resulted in the wrong version of Figure 1 being uploaded. The figure has now been replaced with the correct version in both the PDF and HTML versions of the Article.

Fig. 1.

Fig. 1

..

Footnotes

Edited by S. Tait

These authors contributed equally: Haoran Feng, Kun Liu, Xiaonan Shen.

Contributor Information

Weihua Qiu, Email: qwh11072@rjh.com.cn.

Xi Cheng, Email: drchengxi@126.com.

Ren Zhao, Email: rjzhaoren@139.com.


Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES